Abstract
Three phase 1 pharmacokinetic (PK)/pharmacodynamics (PD) studies were conducted in healthy men and women to further characterize the safety, tolerability, and PK/PD of mirogabalin administration with or without food and to guide the dose selection and regimen for phase 2 and 3 clinical development. The 3 studies included 2 randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose studies, and 1 open-label, crossover study to evaluate the PK of mirogabalin administered under fasting and fed (high-fat meal) conditions. Forty-eight and 47 healthy volunteers completed the single- and multiple-dose studies, respectively. Thirty subjects were enrolled and completed the food effect study. Mirogabalin was well tolerated in the fed and fasted states. The most frequent treatment-emergent adverse events (TEAEs)-dizziness and somnolence-were expected based on mirogabalin's mechanism of action. Subjects receiving the highest mirogabalin doses (50 and 75 mg single dose) showed greater dizziness and sedation and higher rates of TEAEs than subjects receiving 3-30 mg. After oral administration, mirogabalin was rapidly absorbed (time to maximum concentration, ∼1 hour) and eliminated through urine unchanged (61%-72% urinar...Continue Reading
References
Jan 1, 1983·British Journal of Clinical Pharmacology·A C Gudgeon, I Hindmarch
Mar 8, 1996·The Journal of Biological Chemistry·N S GeeG N Woodruff
Jul 21, 2005·Psychological Assessment·Anton Hinton-Bayre, Gina Geffen
Oct 6, 2005·Psychopharmacology·Ian HindmarchFran Ridout
Nov 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mark J FieldDic Williams
Apr 3, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Claudia S BauerAnnette C Dolphin
Jun 30, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Jeremy D SchmahmannMark G Vangel
Feb 12, 2010·Journal of Clinical Pharmacology·Howard N BockbraderDavid L Wesche
Dec 24, 2011·The American Journal of Psychiatry·Kelly PosnerJ John Mann
Aug 24, 2013·Diabetes Care·Solomon TesfayeAnthony H Dickenson
Sep 19, 2014·Diabetes Care·Aaron VinikUNKNOWN DS5565-A-U201 US Phase II Study Investigators
Jan 23, 2015·Health and Quality of Life Outcomes·Masaki KondoTatsuo Akechi
Dec 10, 2015·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators
Mar 5, 2016·Drug, Healthcare and Patient Safety·Santosh BhusalMarina N Magrey
Citations
Feb 20, 2019·Drugs·Emma D Deeks
Apr 14, 2020·PloS One·Hiroshi KitohNaoki Ishiguro
Feb 14, 2020·Pain and Therapy·Masayuki BabaNorimitsu Matsui
Jan 1, 2021·The Korean Journal of Pain·Jae-Yeon KimKyung-Hoon Kim
Jan 26, 2021·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Naotoshi YamamuraVijay Vashi
Feb 13, 2021·Pharmaceuticals·Renata ZajączkowskaJerzy Wordliczek
Jun 2, 2021·Clinical Therapeutics·Jitsu KatoShoichi Ohwada
Aug 26, 2021·Expert Opinion on Pharmacotherapy·Jitsu KatoMasanori Kuroha
Nov 27, 2021·Molecular Pain·Shuji KomatsuTatsuo Yamamoto